Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04462770 · ClinicalTrials.gov registry record · Phase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
A Phase 3 study of Dravet Syndrome, sponsored by Epygenix.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT04462770 is a Phase 3 study of Dravet Syndrome that is actively recruiting participants, run by Epygenix. The registered enrollment target is 150 participants, above the 97-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04462770, a Phase 3 study of Dravet Syndrome, is actively recruiting participants, sponsored by Epygenix.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Clemizole HCl
Study Locations (20)
California
- Children's Hospital of Los Angeles - Los Angeles
- University of California Irvine - Orange
- UCSF Medical Center - San Francisco
Florida
- Rare Disease Research FL - Kissimmee
- Pediatric Neurology and Epilepsy Specialists - Winter Park
New Jersey
- Northeast Regional Epilepsy Group - Hackensack
- Neurology Center for Epilepsy and Seizures - Marlboro
New York
- Weill Cornell Medical Center - New York
- Northwell Health - Lenox Hill Hospital - New York
North Carolina
- Duke University Health System - Durham
- Wake Forest Baptist Medical Center - Winston-Salem
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- The Nemours Foundation - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04462770
The ClinicalTrials.gov registry entry for NCT04462770 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (55% higher). The listed sponsor is Epygenix, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04462770 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04462770 about?
NCT04462770 is a clinical study titled "A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome". This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
What is the current status of trial NCT04462770?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2020-09-15. Estimated completion is 2029-05-01.
What conditions does trial NCT04462770 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT04462770?
The interventions under investigation include: Placebo (DRUG), Clemizole HCl (DRUG).
Who is sponsoring clinical trial NCT04462770?
This trial is sponsored by Epygenix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04462770 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.